Remedium Lifecare unveils Rights Issue post ₹182.7 Cr UK deal to drive Global Expansion

Remedium Lifecare Limited (BSE: 539561) has announced the strategic objectives of its upcoming rights issue, recently approved by the Bombay Stock Exchange (BSE). This capital raise is a cornerstone of the company's transformation into a vertically integrated, research-driven pharmaceutical player, aimed at accelerating global expansion and strengthening operational capabilities.

Remedium Lifecare will invest the proceeds of right issue in research and development to advance its capabilities in complex and high-value pharmaceutical intermediates. Dedicated labs will be established to accelerate R&D across the CNS, metabolic, and oncology verticals-therapeutic areas experiencing strong global demand. The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience. A portion of the proceeds will be allocated to general corporate purposes, including talent acquisition, IT infrastructure upgrades, and international marketing initiatives to expand global reach.

Commenting on the development, Mr. Adarsh Munjal, Managing Director of Remedium Lifecare, said, "The rights issue is a critical step in our long-term strategy to become a global, research-led pharmaceutical company. These investments will further build good Business relations with domestic as well as international organisations across Europe and Asia."

Capital expenditure in a quality control laboratory is vital for enhancing analytical precision and ensuring regulatory compliance. One key feature includes quick baseline stabilization, excellent reproducibility, and fully integrated operation with chromatography systems, specifically designed for isocratic analysis of sugars, polymers, and fatty acids. Analytical systems widely used in chemistry, biochemistry, pharmacology, and environmental science are employed for separating, identifying, and quantifying components in complex mixtures.

Instruments with multi-element capability, using inductively coupled plasma to ionize the sample, enable simultaneous measurement of multiple elements in a single analysis. Advanced mass spectrometry tools, capable of SWATH Acquisition, MRM acquisition, information-dependent high-resolution MS acquisition (IDA), and high-speed MS/MS scanning, can detect analytes with a resolution up to 0.001 atomic mass units, providing highly accurate and detailed results.

Ultraviolet-visible (UV-VIS) spectroscopy systems are used in various scientific fields to analyze compound concentrations, study chemical reactions, and identify substances based on their light absorption. These instruments measure the absorption of ultraviolet and visible light by samples. Infrared (IR) spectroscopy tools are powerful analytical instruments used for studying molecular structures, identifying functional groups, and understanding chemical bonding through the infrared spectrum of absorption or emission.

Furthermore, UV-VIS detectors with high sensitivity and accuracy facilitate the identification of unknown components in matrix systems by detecting and quantifying light absorption in the ultraviolet and visible regions. Lastly, water purification systems are included as capital investments to produce high-quality water used in drug manufacturing. This purified water acts as an excipient in the preparation of sterile and apyrogenic medicines, ensuring the safety and efficacy of pharmaceutical products.

This initiative also reinforces Remedium's commitment to strengthening India's position as a reliable partner in the global pharmaceutical supply chain. By aligning its infrastructure and processes with international standards, the company aims to not only meet stringent regulatory requirements but also drive sustainable growth, create high-value employment, and contribute meaningfully to the 'Make in India' vision for healthcare and life sciences.

Source : Equity Bulls

Keywords

RemediumLifecare FundRaising RightsIssue Objectives